Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma

"Participants will be administered Zanubrutinib orally (PO) via capsules daily during each 28-day cycle at the following dose levels:~* Phase 1 Dose Level 1: 320 mg~* Phase 1 Dose Level -1: 240 mg~* Phase 2: Recommended dose determined in Phase 1."

"Participants will be administered a 12 mg/kg dose of Tafasitamab intravenously (IV) during each 28-day cycle as follows:~* Early Induction - Cycle 1: Days 1, 4, 8, 15, and 22~* Early Induction - Cycles 2 and 3: Days 1, 8, 15 and 22~* Late Induction - Cycles 4 through 12: Days 1 and 15"